Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duopharma Biotech BhdXKLS:7148 -3.85%86 Equity-to-Asset is 0.54 as of Jun. 2026, which is 2% below its 10-year median of 0.55. GuruFocus rates XKLS:7148 with a GF Score™ of 86/100 and a GF Value™ of RM1.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Duopharma Biotech Bhd ranks worse than 59.78% on this metric.
Duopharma Biotech Bhd (XKLS:7148) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Duopharma Biotech Bhd Equity-to-Asset Related Terms
Duopharma Biotech Bhd Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Duopharma Biotech Bhd's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a Equity-to-Asset of 0.54 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Duopharma Biotech Bhd and its competitors. This is near median its historical median of 0.55. Over the past decade, Duopharma Biotech Bhd's Equity-to-Asset has ranged from 0.49 to 0.71. According to the industry distribution chart, Duopharma Biotech Bhd ranks #602 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 59.8%.
Is Duopharma Biotech Bhd's Equity-to-Asset too high?
Duopharma Biotech Bhd's current Equity-to-Asset of 0.54 is near median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 0.71. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Duopharma Biotech Bhd's value of 0.54 is 10% below this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #602 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #602 out of 1007 companies for Equity-to-Asset. This places Duopharma Biotech Bhd in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Duopharma Biotech Bhd's value of 0.54 is 10% below this benchmark. Historically, Duopharma Biotech Bhd's own Equity-to-Asset has ranged from 0.49 to 0.71 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 0.60, Duopharma Biotech Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current Equity-to-Asset of 0.54 is 10% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Equity-to-Asset is 0.54, which is near median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.49, compared to a current price of RM1.25 — trading 16.1% below its estimated fair value. The current Equity-to-Asset is 0.54, which is near median its 10-year median of 0.55 and 10% below the Drug Manufacturers industry median of 0.60. Duopharma Biotech Bhd's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Equity-to-Asset is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.25 is trading 16.1% below its estimated GF Value™ of RM1.49.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Equity-to-Asset: 0.54 (near median its 10-year median of 0.55)
GF Value™: RM1.49 vs. price of RM1.25 (16.1% below fair value)
Industry Position: 10% below the Drug Manufacturers median (#602 of 1007)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
86GF Score
Get the complete analysis for XKLS:7148
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
